Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Ejhaem
|
May 14, 2025
Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia
Gabriel N Mannis, Camille N Abboud, Naval G Daver, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 17, 2017
Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation
Abraham S Kanate, Parameswaran N Hari, Marcelo C Pasquini, et al.
Haematologica
|
May 30, 2024
Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases
Talha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Blood
|
April 15, 2025
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
Naval G Daver, Paresh Vyas, Gerwin A Huls, et al.
Blood Advances
|
May 13, 2024
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
Anand A Patel, James J Yoon, Hannah Johnston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study
David A Sallman, Guillermo Garcia-Manero, Naval Daver, et al.
Blood Advances
|
March 14, 2025
Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations
Anmol Baranwal, Kimberly Langer, Vedavyas Gannamani, et al.
Blood
|
June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia
Eunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Blood Advances
|
October 31, 2025
Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Asparaginase-Treated ALL
Daniela R Anderson, Radhika Gangaraju, Wafik G Sedhom, et al.
Haematologica
|
February 13, 2023
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
Guru Subramanian Guru Murthy, Soyoung Kim, Noel Estrada-Merly, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Ejhaem
|
May 14, 2025
Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia
Gabriel N Mannis, Camille N Abboud, Naval G Daver, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 17, 2017
Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation
Abraham S Kanate, Parameswaran N Hari, Marcelo C Pasquini, et al.
Haematologica
|
May 30, 2024
Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases
Talha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Blood
|
April 15, 2025
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
Naval G Daver, Paresh Vyas, Gerwin A Huls, et al.
Blood Advances
|
May 13, 2024
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
Anand A Patel, James J Yoon, Hannah Johnston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study
David A Sallman, Guillermo Garcia-Manero, Naval Daver, et al.
Blood Advances
|
March 14, 2025
Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations
Anmol Baranwal, Kimberly Langer, Vedavyas Gannamani, et al.
Blood
|
June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia
Eunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Blood Advances
|
October 31, 2025
Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Asparaginase-Treated ALL
Daniela R Anderson, Radhika Gangaraju, Wafik G Sedhom, et al.
Haematologica
|
February 13, 2023
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
Guru Subramanian Guru Murthy, Soyoung Kim, Noel Estrada-Merly, et al.
Page
of 6